Scynexis (SCYX) Tax Provisions (2014 - 2025)
Scynexis' (SCYX) quarterly Tax Provisions came in at -$1.8 million in Q4 2025, up 60.46% on a YoY basis from -$1.1 million in Q4 2024, and up 60.46% quarter-over-quarter from -$4.6 million in Q4 2024.
Analysis
Scynexis (SCYX) Tax Provisions (2014 - 2025) Analysis & Trends
Scynexis (SCYX) has reported Tax Provisions for 8 consecutive years, with -$1.8 million the latest figure, recorded in Q4 2025.
- For the quarter ending Q4 2025, Tax Provisions rose 60.46% year-over-year to -$1.8 million; the trailing twelve-month figure through Dec 2025 stood at -$1.8 million (up 59.24% YoY), and the FY2025 full-year result was -$1.8 million, up 59.32% from the prior year.
- Tax Provisions grew to -$1.8 million in Q4 2025 per SCYX's latest filing, from -$4.6 million in the prior quarter.
- Across five years, Tax Provisions topped out at $14.1 million in Q4 2023 and bottomed at -$8.5 million in Q4 2022.
- Historically, Tax Provisions has averaged -$1.2 million across 5 years, with a median of -$1.8 million in 2025.
- The sharpest annual moves came in 2022 and 2023: Tax Provisions slumped 527.27% in 2022, then jumped 266.45% in 2023.
- Over 5 years, Tax Provisions stood at -$4.7 million in 2021, then sank by 80.61% to -$8.5 million in 2022, then surged by 266.45% to $14.1 million in 2023, then tumbled by 132.37% to -$4.6 million in 2024, then jumped by 60.46% to -$1.8 million in 2025.
- According to Business Quant data, Tax Provisions over the past three periods registered -$1.8 million, -$4.6 million, and -$395000.0 for Q4 2025, Q4 2024, and Q3 2024 respectively.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Taxes (Qtr) |
|---|---|---|---|---|---|
| 1 | Amgen | 236.37 Bn | 222.38 Bn | 7.24 Bn | 393.00 Mn |
| 2 | Gilead Sciences | 187.38 Bn | 184.12 Bn | 6.22 Bn | 242.00 Mn |
| 3 | Vertex Pharmaceuticals | 138.36 Bn | 130.51 Bn | 2.84 Bn | 292.00 Mn |
| 4 | Regeneron Pharmaceuticals | 85.09 Bn | 77.10 Bn | 3.93 Bn | 230.90 Mn |
| 5 | Argenx Se | 63.93 Bn | 58.75 Bn | 1.37 Bn | -59.00 Mn |
| 6 | Moderna | 58.07 Bn | 52.94 Bn | 52.00 Mn | 15.00 Mn |
| 7 | Alnylam Pharmaceuticals | 35.59 Bn | 32.28 Bn | 992.69 Mn | 13.31 Mn |
| 8 | Biogen | 32.63 Bn | 31.34 Bn | 1.96 Bn | 34.90 Mn |
| 9 | Insmed | 27.57 Bn | 26.41 Bn | 358.27 Mn | 1.90 Mn |
| 10 | Scynexis | 52.73 Mn | -61.96 Mn | - | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Dec 31, 2025 | -1.81 Mn |
| Dec 31, 2024 | -4.57 Mn |
| Sep 30, 2024 | -395,000.00 |
| Mar 31, 2024 | 531,000.00 |
| Dec 31, 2023 | 14.11 Mn |
| Dec 31, 2022 | -8.48 Mn |
| Mar 31, 2022 | -4.70 Mn |
| Dec 31, 2021 | -4.69 Mn |
| Sep 30, 2021 | -50,000.00 |
| Jun 30, 2021 | -4.14 Mn |
| Mar 31, 2021 | 1.10 Mn |
| Dec 31, 2020 | -9.11 Mn |
| Jun 30, 2020 | -3.14 Mn |
| Dec 31, 2019 | -11.28 Mn |
| Dec 31, 2014 | -257,000.00 |
| Sep 30, 2014 | -338,000.00 |